These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28345004)

  • 1. Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.
    Hale M; Lee B; Honaker Y; Leung WH; Grier AE; Jacobs HM; Sommer K; Sahni J; Jackson SW; Scharenberg AM; Astrakhan A; Rawlings DJ
    Mol Ther Methods Clin Dev; 2017 Mar; 4():192-203. PubMed ID: 28345004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.
    Sather BD; Romano Ibarra GS; Sommer K; Curinga G; Hale M; Khan IF; Singh S; Song Y; Gwiazda K; Sahni J; Jarjour J; Astrakhan A; Wagner TA; Scharenberg AM; Rawlings DJ
    Sci Transl Med; 2015 Sep; 7(307):307ra156. PubMed ID: 26424571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions enhance virus-free generation of
    Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
    Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System.
    Moço PD; Farnós O; Sharon D; Kamen AA
    Curr Issues Mol Biol; 2023 Sep; 45(10):7705-7720. PubMed ID: 37886930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.
    Hale M; Mesojednik T; Romano Ibarra GS; Sahni J; Bernard A; Sommer K; Scharenberg AM; Rawlings DJ; Wagner TA
    Mol Ther; 2017 Mar; 25(3):570-579. PubMed ID: 28143740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
    Balke-Want H; Keerthi V; Gkitsas N; Mancini AG; Kurgan GL; Fowler C; Xu P; Liu X; Asano K; Patel S; Fisher CJ; Brown AK; Tunuguntla RH; Patel S; Sotillo E; Mackall CL; Feldman SA
    Mol Cancer; 2023 Jun; 22(1):100. PubMed ID: 37365642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy.
    Odé Z; Condori J; Peterson N; Zhou S; Krenciute G
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Automated generation of gene-edited CAR T cells at clinical scale.
    Alzubi J; Lock D; Rhiel M; Schmitz S; Wild S; Mussolino C; Hildenbeutel M; Brandes C; Rositzka J; Lennartz S; Haas SA; Chmielewski KO; Schaser T; Kaiser A; Cathomen T; Cornu TI
    Mol Ther Methods Clin Dev; 2021 Mar; 20():379-388. PubMed ID: 33575430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
    Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
    Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
    Ebert LM; Yu W; Gargett T; Brown MP
    Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of ζ-deficient CARs into the
    Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
    bioRxiv; 2023 Nov; ():. PubMed ID: 38116030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient Enrichment of Gene-Modified Primary T Cells via CCR5-Targeted Integration of Mutant Dihydrofolate Reductase.
    Paul B; Ibarra GSR; Hubbard N; Einhaus T; Astrakhan A; Rawlings DJ; Kiem HP; Peterson CW
    Mol Ther Methods Clin Dev; 2018 Jun; 9():347-357. PubMed ID: 30038938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.
    Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM
    J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma.
    Li S; Xue L; Wang M; Qiang P; Xu H; Zhang X; Kang W; You F; Xu H; Wang Y; Liu X; Yang L; Wang X
    Onco Targets Ther; 2019; 12():5627-5638. PubMed ID: 31372000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.